Milvexian

3 trials

Filter these 3 trials by condition, phase, country and more.

Open in Search →

3 Registered trials

0 Recruiting

3 Completed trials

1 Sponsors

22 Countries

Phase III

Phase III: 3

Oversight events:

2 serious breaches across 2 trials

View oversight register →

Indications tested

Atrial fibrillation 1 Cardiovascular disorder 1

Sponsors using this IMP

Janssen - Cilag International 3

All trials

3 total

LIBREXIA-AF A Phase 3 Active-controlled Study of Milvexian for Prevention of Cardioembolic Events in Participants with Atrial Fibrillation Ended

2022-501419-15-00 Phase III 19 countries Janssen - Cilag International
A Phase 3 Placebo-controlled Study of Milvexian after an Acute Ischemic Stroke or High-Risk Transient Ischemic Attack Ended

2022-501176-26-00 Phase III 22 countries Janssen - Cilag International
A large global trial to evaluate the efficacy and safety of milvexian in reducing recurrent cardiovascular events in patients after a heart … Ended

2022-501418-69-00 Phase III 20 countries Janssen - Cilag International

Showing 1–3 of 3 trials

← All drugs A–Z